Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 674 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Edema Clear all
Completed Not applicable Interventional Results available

Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival

NCT01640171
View directory record Official record
Conditions
Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug
Procedure · Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 30, 2026, 1:29 AM EDT
Completed No phase listed Observational

Evaluating for Contact Allergies in Patients With Chronic Urticaria

NCT00868036
View directory record Official record
Conditions
Urticaria, Patch Testing, Dermatitis, Allergy, Contact Sensitization
Interventions
Patch Testing
Procedure
Lead sponsor
Tufts Medical Center
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 30, 2026, 1:29 AM EDT
Terminated Not applicable Interventional Results available

Timing of PDA Closure and Respiratory Outcome in Premature Infants

NCT00802685
View directory record Official record
Conditions
Patent Ductus Arteriosus
Interventions
Early ibuprofen, Late ibuprofen expectant group (placebo)
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
1 Day to 14 Days
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Oct 30, 2026, 1:29 AM EDT
Not listed Phase 3 Interventional

Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19

NCT04433949
View directory record Official record
Conditions
Pneumonia, Severe Acute Respiratory Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Low Dose Radiation Therapy
Other · Radiation
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 30, 2026, 1:29 AM EDT
Withdrawn Phase 2 Interventional

Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids

NCT00846625
View directory record Official record
Conditions
Macular Edema, Uveitis
Interventions
triamcinolone, ranibizumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 30, 2026, 1:29 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06957080
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
Remigromig, Ranibizumab
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
107
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 1:29 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Lucentis (Ranibizumab) for Eales' Disease

NCT00384449
View directory record Official record
Conditions
Eales' Disease
Interventions
Ranibizumab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 30, 2026, 1:29 AM EDT
Terminated Phase 3 Interventional

Macular Edema Incidence/Severity Reduction With Nevanac

NCT00939276
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Nepafenac ophthalmic suspension, 0.1% (NEVANAC®), Nepafenac ophthalmic suspension vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 30, 2026, 1:29 AM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

NCT03810313
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 30, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema

NCT02712008
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
REGN910-3, Intravitreal Aflibercept Injection (IAI)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
51
States / cities
Mesa, Arizona • Tucson, Arizona • Arcadia, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 30, 2026, 1:29 AM EDT
Completed Phase 4 Interventional

Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure

NCT00115726
View directory record Official record
Conditions
Hypertension, Hypotension, Edema, Congestive Heart Failure
Interventions
furosemide, placebo
Drug
Lead sponsor
University of Calgary
Other
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2008 · Synced Oct 30, 2026, 1:29 AM EDT
Completed Phase 2 Interventional

Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy

NCT07501052
View directory record Official record
Conditions
Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
SCD411 0.05mL (2mg)
Drug
Lead sponsor
Sam Chun Dang Pharm. Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Stuart, Florida • Winter Haven, Florida • Lemont, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 30, 2026, 1:29 AM EDT
Completed Phase 2 Interventional

Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

NCT06099184
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
6
States / cities
Phoenix, Arizona • Lemont, Illinois • Hagerstown, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 30, 2026, 1:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Measuring Volume Using a 3D Scanner and iPad to Grade the Swelling of Legs

NCT06944041
View directory record Official record
Conditions
Limb Volume, Measuring Edema
Interventions
STO3 sensor (Structure Inc., Boulder, CO)
Other
Lead sponsor
The RANE Center for Venous and Lymphatic Diseases at St. Dominic's Hospital
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 30, 2026, 1:29 AM EDT
Completed Phase 3 Interventional

Laser and Medical Treatment of Diabetic Macular Edema

NCT00050479
View directory record Official record
Conditions
Macular Degeneration
Interventions
Celecoxib (Celebrex)
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 30, 2026, 1:29 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography

NCT01790945
View directory record Official record
Conditions
Mild Nonproliferative Diabetic Retinopathy, Moderate Nonproliferative Diabetic Retinopathy, Severe Nonproliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Not listed
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Hilo, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Oct 30, 2026, 1:29 AM EDT
Withdrawn No phase listed Observational

Study to Evaluate Bacterial Activity That Drives the Progression of Clinical Infection

NCT03854695
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 30, 2026, 1:29 AM EDT
Completed No phase listed Observational

The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease

NCT00331331
View directory record Official record
Conditions
Uveitis, Vasculitis, Ocular Inflammatory Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 30, 2026, 1:29 AM EDT
Terminated No phase listed Observational

Descemet Membrane Endothelial Keratoplasty vs. Descemet's Stripping With Endothelial Keratoplasty vs. Descemet Stripping Only

NCT04527523
View directory record Official record
Conditions
Cystoid Macular Edema, Fuchs Dystrophy
Interventions
Optical Coherence Tomography
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 30, 2026, 1:29 AM EDT
Completed No phase listed Observational Results available

Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)

NCT01411696
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
dexamethasone intravitreal implant 0.7 mg
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Oct 30, 2026, 1:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema

NCT00403039
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Ranibizumab (Lucentis )
Drug
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 30, 2026, 1:29 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)

NCT06847854
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
RO7497372
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 1:29 AM EDT
Not listed Not applicable Interventional

Supplemental Adjuvants for Intracellular Nutrition and Treatment

NCT00893724
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions
Neutral pills with no medicinal effect, Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals, Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline
Drug · Dietary Supplement
Lead sponsor
Mid-Atlantic Retina Consultations, Inc.
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 30, 2026, 1:29 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser

NCT00491166
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Bromfenac ophthalmic solution
Drug
Lead sponsor
Ophthalmic Consultants of Boston
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2007 · Synced Oct 30, 2026, 1:29 AM EDT